| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
|
N Engl J Med
|
2009
|
28.62
|
|
2
|
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
|
N Engl J Med
|
2012
|
12.98
|
|
3
|
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.
|
Nature
|
2012
|
5.49
|
|
4
|
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.
|
Immunity
|
2013
|
4.82
|
|
5
|
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.
|
Nature
|
2012
|
3.83
|
|
6
|
Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection.
|
PLoS One
|
2012
|
3.69
|
|
7
|
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.
|
J Infect Dis
|
2012
|
2.89
|
|
8
|
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.
|
Cell
|
2013
|
2.88
|
|
9
|
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.
|
J Virol
|
2012
|
2.74
|
|
10
|
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.
|
Proc Natl Acad Sci U S A
|
2013
|
2.69
|
|
11
|
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.
|
Lancet Infect Dis
|
2012
|
2.68
|
|
12
|
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.
|
Sci Transl Med
|
2014
|
2.47
|
|
13
|
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.
|
AIDS Res Hum Retroviruses
|
2012
|
1.94
|
|
14
|
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
|
PLoS One
|
2013
|
1.94
|
|
15
|
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.
|
Sci Transl Med
|
2014
|
1.87
|
|
16
|
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.
|
J Immunol
|
2012
|
1.75
|
|
17
|
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.
|
PLoS One
|
2013
|
1.65
|
|
18
|
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
|
J Infect Dis
|
2012
|
1.65
|
|
19
|
Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.
|
J Infect Dis
|
2011
|
1.55
|
|
20
|
A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
|
Antivir Ther
|
2012
|
1.48
|
|
21
|
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
|
J Acquir Immune Defic Syndr
|
2007
|
1.39
|
|
22
|
Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.
|
Expert Rev Vaccines
|
2010
|
1.31
|
|
23
|
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.
|
J Virol
|
2013
|
1.26
|
|
24
|
Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection.
|
PLoS One
|
2012
|
1.25
|
|
25
|
Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion.
|
J Virol
|
2012
|
1.24
|
|
26
|
Incidence and characterization of acute HIV-1 infection in a high-risk Thai population.
|
J Acquir Immune Defic Syndr
|
2008
|
1.24
|
|
27
|
A novel acute HIV infection staging system based on 4th generation immunoassay.
|
Retrovirology
|
2013
|
1.24
|
|
28
|
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.
|
J Clin Invest
|
2014
|
1.18
|
|
29
|
HIV type 1 molecular epidemiology among high-risk clients attending the Thai Red Cross Anonymous Clinic in Bangkok, Thailand.
|
AIDS Res Hum Retroviruses
|
2010
|
1.07
|
|
30
|
Human immunodeficiency virus vaccine trials.
|
Cold Spring Harb Perspect Med
|
2012
|
1.05
|
|
31
|
Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.
|
PLoS One
|
2013
|
1.04
|
|
32
|
Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.
|
Virology
|
2005
|
1.04
|
|
33
|
HIV-1 Vpr activates cell cycle inhibitor p21/Waf1/Cip1: a potential mechanism of G2/M cell cycle arrest.
|
Virology
|
2003
|
1.00
|
|
34
|
Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection.
|
AIDS
|
2015
|
0.99
|
|
35
|
Class I HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania.
|
J Infect Dis
|
2010
|
0.98
|
|
36
|
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.
|
PLoS One
|
2011
|
0.93
|
|
37
|
Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.
|
PLoS One
|
2012
|
0.93
|
|
38
|
HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses.
|
PLoS One
|
2012
|
0.92
|
|
39
|
Distinct gene-expression profiles associated with the susceptibility of pathogen-specific CD4 T cells to HIV-1 infection.
|
Blood
|
2012
|
0.92
|
|
40
|
The immune space: a concept and template for rationalizing vaccine development.
|
AIDS Res Hum Retroviruses
|
2014
|
0.92
|
|
41
|
Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial.
|
J Virol
|
2013
|
0.91
|
|
42
|
HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial.
|
Immunogenetics
|
2014
|
0.90
|
|
43
|
Expression of monocyte markers in HIV-1 infected individuals with or without HIV associated dementia and normal controls in Bangkok Thailand.
|
J Neuroimmunol
|
2008
|
0.89
|
|
44
|
Viral and host factors associated with the HIV-1 viral load setpoint in adults from Mbeya Region, Tanzania.
|
J Acquir Immune Defic Syndr
|
2010
|
0.89
|
|
45
|
Cell type-specific proteasomal processing of HIV-1 Gag-p24 results in an altered epitope repertoire.
|
J Virol
|
2010
|
0.88
|
|
46
|
Human T-cell leukemia virus type 1 Tax activates cyclin-dependent kinase inhibitor p21/Waf1/Cip1 expression through a p53-independent mechanism: Inhibition of cdk2.
|
Int J Cancer
|
2003
|
0.87
|
|
47
|
High-throughput multiplex HLA genotyping by next-generation sequencing using multi-locus individual tagging.
|
BMC Genomics
|
2014
|
0.87
|
|
48
|
An investigation of bloodborne pathogen transmission due to multipatient sharing of insulin pens.
|
Mil Med
|
2012
|
0.87
|
|
49
|
Comparison between env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults.
|
J Acquir Immune Defic Syndr
|
2003
|
0.85
|
|
50
|
HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E.
|
Vaccine
|
2011
|
0.85
|
|
51
|
Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone.
|
PLoS One
|
2013
|
0.83
|
|
52
|
HIV-associated wasting in the era of highly active antiretroviral therapy: a syndrome of residual HIV infection in monocytes and macrophages?
|
Clin Infect Dis
|
2005
|
0.83
|
|
53
|
Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants.
|
Clin Vaccine Immunol
|
2014
|
0.82
|
|
54
|
Hepatitis C genotype distribution and homology among geographically disparate injecting drug users in Afghanistan.
|
J Med Virol
|
2013
|
0.82
|
|
55
|
Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.
|
J Infect Dis
|
2004
|
0.82
|
|
56
|
Centralized HIV Program Oversight.
|
Medicine (Baltimore)
|
2015
|
0.82
|
|
57
|
Implications of hepatitis C viremia vs. antibody alone on transmission among male injecting drug users in three Afghan cities.
|
Int J Infect Dis
|
2010
|
0.81
|
|
58
|
Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
|
Vaccine
|
2012
|
0.80
|
|
59
|
RecDraw: a software package for the representation of HIV-1 recombinant structures.
|
AIDS Res Hum Retroviruses
|
2010
|
0.80
|
|
60
|
High prevalence of transmitted drug resistance in acute HIV-infected Thai men who have sex with men.
|
J Acquir Immune Defic Syndr
|
2015
|
0.79
|
|
61
|
Transfusion-transmitted human T-lymphotropic virus Type I infection in a United States military emergency whole blood transfusion recipient in Afghanistan, 2010.
|
Transfusion
|
2013
|
0.79
|
|
62
|
Molecular epidemiology of early and acute HIV type 1 infections in the United States Navy and Marine Corps, 2005-2010.
|
AIDS Res Hum Retroviruses
|
2013
|
0.79
|
|
63
|
Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals.
|
AIDS
|
2016
|
0.79
|
|
64
|
Brief Report: Sexual Risk Behaviors of HIV Seroconverters in the US Army, 2012-2014.
|
J Acquir Immune Defic Syndr
|
2015
|
0.79
|
|
65
|
Nautilus: a bioinformatics package for the analysis of HIV type 1 targeted deep sequencing data.
|
AIDS Res Hum Retroviruses
|
2013
|
0.78
|
|
66
|
Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis.
|
PLoS Med
|
2015
|
0.78
|
|
67
|
Inhibition of HIV-1 infection of peripheral blood mononuclear cells by a monoclonal antibody that binds to phosphoinositides and induces secretion of β-chemokines.
|
Biochem Biophys Res Commun
|
2010
|
0.78
|
|
68
|
Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).
|
AIDS
|
2012
|
0.78
|
|
69
|
Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.
|
Emerg Infect Dis
|
2016
|
0.78
|
|
70
|
Natural killer cell-mediated innate sieve effect on HIV-1: the impact of KIR/HLA polymorphism on HIV-1 subtype-specific acquisition in east Africa.
|
J Infect Dis
|
2013
|
0.77
|
|
71
|
Histoplasmosis and penicilliosis among HIV-infected Thai patients: a retrospective review.
|
Southeast Asian J Trop Med Public Health
|
2012
|
0.77
|
|
72
|
W-curve alignments for HIV-1 genomic comparisons.
|
PLoS One
|
2010
|
0.76
|
|
73
|
The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
|
Expert Rev Vaccines
|
2014
|
0.76
|
|
74
|
Timing, adherence, resistance, and ... persistence? new insight into the mechanisms of failure of HIV type 1 postexposure prophylaxis.
|
J Infect Dis
|
2013
|
0.76
|
|
75
|
Two unique recombinant forms identified in incident HIV type 1 infections in Thai blood donors.
|
AIDS Res Hum Retroviruses
|
2012
|
0.76
|
|
76
|
Significant contribution of subtype G to HIV-1 genetic complexity in Nigeria identified by a newly developed subtyping assay specific for subtype G and CRF02_AG.
|
Medicine (Baltimore)
|
2016
|
0.76
|
|
77
|
Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.
|
PLoS Pathog
|
2017
|
0.75
|
|
78
|
Use of dried blood spots for HIV-1 genotyping in Southeast Asia: Thailand experience.
|
Southeast Asian J Trop Med Public Health
|
2012
|
0.75
|
|
79
|
Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection.
|
PLoS Pathog
|
2017
|
0.75
|
|
80
|
Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.
|
Nat Med
|
2016
|
0.75
|
|
81
|
HIV vaccines moving forward.
|
Curr Opin HIV AIDS
|
2016
|
0.75
|